Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1094

1.

Sample selection and reasons for non-participation in the PRedictors and Outcomes of incident FRACtures (PROFRAC) study.

Stuart AL, Pasco JA, Brennan-Olsen SL, Berk M, Betson AG, Bennett KE, Timney EN, Williams LJ.

J Public Health Res. 2019 May 3;8(1):1475. doi: 10.4081/jphr.2019.1475. eCollection 2019 Mar 11.

2.

A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence.

McKetin R, Dean OM, Turner A, Kelly PJ, Quinn B, Lubman DI, Dietze P, Carter G, Higgs P, Baker AL, Sinclair B, Reid D, Manning V, Te Pas N, Liang W, Thomas T, Bathish R, Kent M, Raftery D, Arunogiri S, Cordaro F, Hill H, Berk M.

Trials. 2019 Jun 4;20(1):325. doi: 10.1186/s13063-019-3450-0.

3.

Unravelled facets of milk derived opioid peptides: a focus on gut physiology, fractures and obesity.

Aslam H, Ruusunen A, Berk M, Loughman A, Rivera L, Pasco JA, Jacka FN.

Int J Food Sci Nutr. 2019 Jun 3:1-14. doi: 10.1080/09637486.2019.1614540. [Epub ahead of print]

PMID:
31154909
4.

The Potential of Carnosine in Brain-Related Disorders: A Comprehensive Review of Current Evidence.

Schön M, Mousa A, Berk M, Chia WL, Ukropec J, Majid A, Ukropcová B, de Courten B.

Nutrients. 2019 May 28;11(6). pii: E1196. doi: 10.3390/nu11061196. Review.

5.

Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis.

Marx W, Lane M, Rocks T, Ruusunen A, Loughman A, Lopresti A, Marshall S, Berk M, Jacka F, Dean OM.

Nutr Rev. 2019 May 28. pii: nuz023. doi: 10.1093/nutrit/nuz023. [Epub ahead of print]

PMID:
31135916
6.

Does stage of illness influence recovery-focused outcomes after psychological treatment in bipolar disorder? A systematic review protocol.

Tremain H, Fletcher K, Scott J, McEnery C, Berk M, Murray G.

Syst Rev. 2019 May 25;8(1):125. doi: 10.1186/s13643-019-1042-4.

7.

Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial.

Kavanagh BE, Williams LJ, Berk M, Turner A, Jackson HJ, Mohebbi M, Kanchanatawan B, Ashton MM, Ng CH, Maes M, Berk L, Malhi GS, Dowling N, Singh AB, Dean OM.

Braz J Psychiatry. 2019 May 16. pii: S1516-44462019005008104. doi: 10.1590/1516-4446-2018-0308. [Epub ahead of print]

8.

Biomarker-Guided Anti-inflammatory Therapies: From Promise to Reality Check.

Berk M, Walker AJ, Nierenberg AA.

JAMA Psychiatry. 2019 May 8. doi: 10.1001/jamapsychiatry.2019.0673. [Epub ahead of print] No abstract available.

PMID:
31066892
9.

Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study.

Agustini B, Mohebbi M, Woods RL, McNeil JJ, Nelson MR, Shah RC, Murray AM, Ernst ME, Reid CM, Tonkin A, Lockery JE, Berk M; ASPREE Investigator Group.

CNS Drugs. 2019 May 6. doi: 10.1007/s40263-019-00633-3. [Epub ahead of print]

PMID:
31062260
10.

Role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders: a protocol for a systematic review and meta-analysis.

Kavanagh BE, Brennan-Olsen SL, Turner A, Dean OM, Berk M, Ashton MM, Koivumaa-Honkanen H, Williams LJ.

BMJ Open. 2019 May 1;9(4):e025145. doi: 10.1136/bmjopen-2018-025145.

11.

Co-occurrence of depression with chronic diseases among the older population living in low- and middle-income countries: A compound health challenge.

Lotfaliany M, Agustini B, Kowal P, Berk M, Mohebbi M.

Ann Clin Psychiatry. 2019 May;31(2):95-105.

PMID:
31046030
12.

Supporting Engagement, Adherence, and Behavior Change in Online Dietary Interventions.

Young C, Campolonghi S, Ponsonby S, Dawson SL, O'Neil A, Kay-Lambkin F, McNaughton SA, Berk M, Jacka FN.

J Nutr Educ Behav. 2019 Jun;51(6):719-739. doi: 10.1016/j.jneb.2019.03.006. Epub 2019 Apr 27.

PMID:
31036500
13.

Prevalence of depressive symptoms and its associated factors among healthy community-dwelling older adults living in Australia and the United States.

Mohebbi M, Agustini B, Woods RL, McNeil JJ, Nelson MR, Shah RC, Nguyen V, Storey E, Murray AM, Reid CM, Kirpach B, Wolfe R, Lockery JE, Berk M; ASPREE Investigator Group.

Int J Geriatr Psychiatry. 2019 Apr 16. doi: 10.1002/gps.5119. [Epub ahead of print]

PMID:
30989707
14.

Childbirth and prevention of bipolar disorder: an opportunity for change.

Sharma V, Bergink V, Berk M, Chandra PS, Munk-Olsen T, Viguera AC, Yatham LN.

Lancet Psychiatry. 2019 Apr 10. pii: S2215-0366(19)30092-6. doi: 10.1016/S2215-0366(19)30092-6. [Epub ahead of print] Review.

PMID:
30981755
15.

Protocol update and statistical analysis plan for CADENCE-BZ: a randomized clinical trial to assess the efficacy of sodium benzoate as an adjunctive treatment in early psychosis.

Lim C, Baker A, Saha S, Foley S, Gordon A, Ward D, Burgher B, Dark F, Beckmann M, Stathis S, Bruxner G, Ryan A, Richardson D, Hatherill S, Berk M, Dean O, McGrath J; Cadence Working Group, Scott J.

Trials. 2019 Apr 8;20(1):203. doi: 10.1186/s13063-019-3232-8.

16.

Faecal microbiota transplants for depression - Who gives a crapsule?

Green J, Castle D, Berk M, Hair C, Loughman A, Cryan J, Nierenberg A, Athan E, Jacka F.

Aust N Z J Psychiatry. 2019 Apr 8:4867419839776. doi: 10.1177/0004867419839776. [Epub ahead of print] No abstract available.

PMID:
30957511
17.

Nutraceuticals and nutritional supplements for the treatment of bipolar disorder: protocol for a systematic review.

Ashton MM, Berk M, Ng CH, Hopwood M, Kavanagh B, Williams LJ, Sarris J, Dean OM.

BMJ Open. 2019 Apr 4;9(4):e025640. doi: 10.1136/bmjopen-2018-025640.

18.

Variation in the prevalence of depression and patterns of association, sociodemographic and lifestyle factors in community-dwelling older adults in six low- and middle-income countries.

Lotfaliany M, Hoare E, Jacka FN, Kowal P, Berk M, Mohebbi M.

J Affect Disord. 2019 May 15;251:218-226. doi: 10.1016/j.jad.2019.01.054. Epub 2019 Mar 18.

PMID:
30927583
19.

The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia.

Ashton MM, Dean OM, Walker AJ, Bortolasci CC, Ng CH, Hopwood M, Harvey BH, Möller M, McGrath JJ, Marx W, Turner A, Dodd S, Scott JG, Khoo JP, Walder K, Sarris J, Berk M.

Front Psychiatry. 2019 Mar 13;10:115. doi: 10.3389/fpsyt.2019.00115. eCollection 2019. Review.

20.

Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity - a consensus of the Biomarkers Task Force from the WFSBP.

Andreazza AC, Laksono I, Fernandes BS, Toben C, Lewczuk P, Riederer P, Kennedy SH, Kapogiannis D, Thibaut F, Gerlach M, Gallo C, Kim YK, Grünblatt E, Yatham L, Berk M, Baune BT.

World J Biol Psychiatry. 2019 Mar 25:1-12. doi: 10.1080/15622975.2019.1574024. [Epub ahead of print]

PMID:
30907211
21.

Parental Validation and Invalidation Predict Adolescent Self-Harm.

Adrian M, Berk MS, Korslund K, Whitlock K, McCauley E, Linehan M.

Prof Psychol Res Pr. 2018 Aug;49(4):274-281. doi: 10.1037/pro0000200.

PMID:
30906109
22.

Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive Garcinia mangostanaLinn. (Mangosteen) Pericarp for Schizophrenia.

Turner A, McGrath JJ, Dean OM, Dodd S, Baker A, Cotton SM, Scott JG, Kavanagh BE, Ashton MM, Walker AJ, Brown E, Berk M.

Clin Psychopharmacol Neurosci. 2019 May 31;17(2):297-307. doi: 10.9758/cpn.2019.17.2.297.

23.

Statins and Inflammation: New Therapeutic Opportunities in Psychiatry.

Kim SW, Kang HJ, Jhon M, Kim JW, Lee JY, Walker AJ, Agustini B, Kim JM, Berk M.

Front Psychiatry. 2019 Mar 5;10:103. doi: 10.3389/fpsyt.2019.00103. eCollection 2019. Review.

24.

Association between solar insolation and a history of suicide attempts in bipolar I disorder.

Bauer M, Glenn T, Alda M, Andreassen OA, Angelopoulos E, Ardau R, Ayhan Y, Baethge C, Bauer R, Baune BT, Becerra-Palars C, Bellivier F, Belmaker RH, Berk M, Bersudsky Y, Bicakci Ş, Birabwa-Oketcho H, Bjella TD, Cabrera J, Wo Cheung EY, Del Zompo M, Dodd S, Donix M, Etain B, Fagiolini A, Fountoulakis KN, Frye MA, Gonzalez-Pinto A, Gottlieb JF, Grof P, Harima H, Henry C, Isometsä ET, Janno S, Kapczinski F, Kardell M, Khaldi S, Kliwicki S, König B, Kot TL, Krogh R, Kunz M, Lafer B, Landén M, Larsen ER, Lewitzka U, Licht RW, Lopez-Jaramillo C, MacQueen G, Manchia M, Marsh W, Martinez-Cengotitabengoa M, Melle I, Meza-Urzúa F, Ming MY, Monteith S, Morken G, Mosca E, Mozzhegorov AA, Munoz R, Mythri SV, Nacef F, Nadella RK, Nery FG, Nielsen RE, O'Donovan C, Omrani A, Osher Y, Sørensen HØ, Ouali U, Ruiz YP, Pilhatsch M, Pinna M, da Ponte FDR, Quiroz D, Ramesar R, Rasgon N, Reddy MS, Reif A, Ritter P, Rybakowski JK, Sagduyu K, Raghuraman BS, Scippa ÂM, Severus E, Simhandl C, Stackhouse PW Jr, Stein DJ, Strejilevich S, Subramaniam M, Sulaiman AH, Suominen K, Tagata H, Tatebayashi Y, Tondo L, Torrent C, Vaaler AE, Vares E, Veeh J, Vieta E, Viswanath B, Yoldi-Negrete M, Zetin M, Zgueb Y, Whybrow PC.

J Psychiatr Res. 2019 Jun;113:1-9. doi: 10.1016/j.jpsychires.2019.03.001. Epub 2019 Mar 8.

PMID:
30878786
25.

New drug candidates for bipolar disorder-A nation-wide population-based study.

Kessing LV, Rytgaard HC, Gerds TA, Berk M, Ekstrøm CT, Andersen PK.

Bipolar Disord. 2019 Mar 14. doi: 10.1111/bdi.12772. [Epub ahead of print]

PMID:
30873730
26.

Buffering against maladaptive perfectionism in bipolar disorder: The role of self-compassion.

Fletcher K, Yang Y, Johnson SL, Berk M, Perich T, Cotton S, Jones S, Lapsley S, Michalak E, Murray G.

J Affect Disord. 2019 May 1;250:132-139. doi: 10.1016/j.jad.2019.03.003. Epub 2019 Mar 4.

PMID:
30852365
27.

Diet and Depression-From Confirmation to Implementation.

Berk M, Jacka FN.

JAMA. 2019 Mar 5;321(9):842-843. doi: 10.1001/jama.2019.0273. No abstract available.

PMID:
30835294
28.

Treatment-resistant and Multi-therapy resistant criteria for bipolar depression: consensus definition - CORRIGENDUM.

Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Di Florio A, Dietch D, Geddes JR, Goodwin GM, Grunze H, Hayes JF, Jones I, Kasper S, Macritchie K, Hamish McAllister-Williams R, Morriss R, Nayrouz S, Pappa S, Soares JC, Smith DJ, Suppes T, Talbot P, Vieta E, Watson S, Yatham LN, Young AH, Stokes PRA.

Br J Psychiatry. 2019 May;214(5):309. doi: 10.1192/bjp.2019.36. Epub 2019 Feb 28. No abstract available.

PMID:
30816078
29.

Development of a miniature device for emerging deep brain stimulation paradigms.

Adams SD, Bennet KE, Tye SJ, Berk M, Kouzani AZ.

PLoS One. 2019 Feb 21;14(2):e0212554. doi: 10.1371/journal.pone.0212554. eCollection 2019.

30.

Better research, better evidence, better access.

Berk M.

Aust N Z J Psychiatry. 2019 Feb;53(2):97-98. doi: 10.1177/0004867418824024. No abstract available.

PMID:
30788988
31.

Bipolar disorder and bone health: A systematic review.

Chandrasekaran V, Brennan-Olsen SL, Stuart AL, Pasco JA, Berk M, Hodge JM, Williams LJ.

J Affect Disord. 2019 Apr 15;249:262-269. doi: 10.1016/j.jad.2019.02.013. Epub 2019 Feb 6.

PMID:
30784723
32.

Correction to: A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo.

Berk M, Turner A, Malhi GS, Ng CH, Cotton SM, Dodd S, Samuni Y, Tanious M, McAulay C, Dowling N, Sarris J, Owen L, Waterdrinker A, Smith D, Dean OM.

BMC Med. 2019 Feb 17;17(1):35. doi: 10.1186/s12916-019-1280-2.

33.

Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop?

Morris G, Maes M, Berk M, Puri BK.

Metab Brain Dis. 2019 Apr;34(2):385-415. doi: 10.1007/s11011-019-0388-6. Epub 2019 Feb 13. Review.

34.

Improving functional outcomes in early-stage bipolar disorder: The protocol for the REsearch into COgnitive and behavioural VERsatility trial.

Cotton SM, Berk M, Jackson H, Murray G, Filia K, Hasty M, Chanen A, Davey C, Nelson B, Ratheesh A, MacNeil C.

Early Interv Psychiatry. 2019 Feb 10. doi: 10.1111/eip.12797. [Epub ahead of print]

PMID:
30740882
35.

The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: A randomized placebo-controlled study.

Ellegaard PK, Licht RW, Nielsen RE, Dean OM, Berk M, Poulsen HE, Mohebbi M, Nielsen CT.

J Affect Disord. 2019 Feb 15;245:1043-1051. doi: 10.1016/j.jad.2018.10.083. Epub 2018 Oct 6.

PMID:
30699846
36.

Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial.

Sarris J, Byrne GJ, Stough C, Bousman C, Mischoulon D, Murphy J, Macdonald P, Adams L, Nazareth S, Oliver G, Cribb L, Savage K, Menon R, Chamoli S, Berk M, Ng CH.

J Affect Disord. 2019 Feb 15;245:1007-1015. doi: 10.1016/j.jad.2018.11.092. Epub 2018 Nov 13.

PMID:
30699842
37.

Putative neuroprotective pharmacotherapies to target the staged progression of mental illness.

Robertson OD, Coronado NG, Sethi R, Berk M, Dodd S.

Early Interv Psychiatry. 2019 Jan 28. doi: 10.1111/eip.12775. [Epub ahead of print] Review.

PMID:
30690898
38.

Socioeconomic Deprivation, Adverse Childhood Experiences and Medical Disorders in Adulthood: Mechanisms and Associations.

Morris G, Berk M, Maes M, Carvalho AF, Puri BK.

Mol Neurobiol. 2019 Jan 26. doi: 10.1007/s12035-019-1498-1. [Epub ahead of print] Review.

PMID:
30685844
39.

A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo.

Berk M, Turner A, Malhi GS, Ng CH, Cotton SM, Dodd S, Samuni Y, Tanious M, McAulay C, Dowling N, Sarris J, Owen L, Waterdrinker A, Smith D, Dean OM.

BMC Med. 2019 Jan 25;17(1):18. doi: 10.1186/s12916-019-1257-1. Erratum in: BMC Med. 2019 Feb 17;17(1):35.

40.

The impact of urbanization on mood disorders: an update of recent evidence.

Hoare E, Jacka F, Berk M.

Curr Opin Psychiatry. 2019 May;32(3):198-203. doi: 10.1097/YCO.0000000000000487.

PMID:
30676331
41.

Rheumatoid meningitis sine arthritis.

Lee Ching C, Kenyon L, Berk M, Park C.

J Neuroimmunol. 2019 Mar 15;328:73-75. doi: 10.1016/j.jneuroim.2018.12.001. Epub 2018 Dec 19.

PMID:
30597393
42.

The SMILES trial: an important first step.

Jacka FN, O'Neil A, Itsiopoulos C, Opie R, Cotton S, Mohebbi M, Castle D, Dash S, Mihalopoulos C, Chatterton ML, Brazionis L, Dean OM, Hodge A, Berk M.

BMC Med. 2018 Dec 28;16(1):237. doi: 10.1186/s12916-018-1228-y.

43.

Correction to: A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial).

Jacka FN, O'Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, Castle D, Dash S, Mihalopoulos C, Chatterton ML, Brazionis L, Dean OM, Hodge AM, Berk M.

BMC Med. 2018 Dec 28;16(1):236. doi: 10.1186/s12916-018-1220-6.

44.

Association between childhood trauma exposure and pro-inflammatory cytokines in schizophrenia and bipolar-I disorder.

Quidé Y, Bortolasci CC, Spolding B, Kidnapillai S, Watkeys OJ, Cohen-Woods S, Berk M, Carr VJ, Walder K, Green MJ.

Psychol Med. 2018 Dec 18:1-9. doi: 10.1017/S0033291718003690. [Epub ahead of print]

PMID:
30560764
45.

Toward Precision Psychiatry in Bipolar Disorder: Staging 2.0.

Salagre E, Dodd S, Aedo A, Rosa A, Amoretti S, Pinzon J, Reinares M, Berk M, Kapczinski FP, Vieta E, Grande I.

Front Psychiatry. 2018 Nov 29;9:641. doi: 10.3389/fpsyt.2018.00641. eCollection 2018. Review.

46.

WFSBP guidelines on how to grade treatment evidence for clinical guideline development.

Hasan A, Bandelow B, Yatham LN, Berk M, Falkai P, Möller HJ, Kasper S; WFSBP Guideline Task Force Chairs.

World J Biol Psychiatry. 2019 Jan;20(1):2-16. doi: 10.1080/15622975.2018.1557346. Epub 2019 Feb 4. Review.

PMID:
30526182
47.

Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.

Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Florio AD, Dietch D, Geddes JR, Goodwin GM, Grunze H, Hayes JF, Jones I, Kasper S, Macritchie K, McAllister-Williams RH, Morriss R, Nayrouz S, Pappa S, Soares JC, Smith DJ, Suppes T, Talbot P, Vieta E, Watson S, Yatham LN, Young AH, Stokes PRA.

Br J Psychiatry. 2019 Jan;214(1):27-35. doi: 10.1192/bjp.2018.257. Epub 2018 Dec 6. Erratum in: Br J Psychiatry. 2019 May;214(5):309.

PMID:
30520709
48.

Considerations when selecting pharmacotherapy for nicotine dependence.

Dodd S, Arancini L, Gómez-Coronado N, Gasser R, Lubman DI, Dean OM, Berk M.

Expert Opin Pharmacother. 2019 Feb;20(3):245-250. doi: 10.1080/14656566.2018.1550072. Epub 2018 Nov 29. No abstract available.

PMID:
30496692
49.

Fermented foods, the gut and mental health: a mechanistic overview with implications for depression and anxiety.

Aslam H, Green J, Jacka FN, Collier F, Berk M, Pasco J, Dawson SL.

Nutr Neurosci. 2018 Nov 11:1-13. doi: 10.1080/1028415X.2018.1544332. [Epub ahead of print]

PMID:
30415609
50.

Medications With Depression as an Adverse Effect.

Agustini B, Berk M.

JAMA. 2018 Nov 6;320(17):1815. doi: 10.1001/jama.2018.12390. No abstract available.

PMID:
30398595

Supplemental Content

Support Center